同種細胞療法の世界市場レポート 2024年

同種細胞療法の市場規模は、今後数年で急成長が見込まれます。2028年にはCAGR11.6%で16億7,000万米ドルに成長します。この予測における成長の原動力は、先進医療に対する需要の高まり、革新的な同種細胞療法に対するニーズの急増、臨床試験活動の急増、患者集団からの貢献の増大、所得水準の上昇です。予測期間中に予想される注目すべき動向としては、技術の進歩、戦略的パートナーシップ、大手企業間の提携、M&A、新製品のイントロダクションなどが挙げられます。

慢性疾患の増加は、同種細胞療法市場の拡大を促進すると予想されます。慢性疾患は、長期にわたる罹患を特徴とし、継続的な治療を必要とするため、日常生活に支障をきたし、生活の質を低下させる。これらの疾患の蔓延は、生活習慣の変化、遺伝、環境毒素や汚染物質への曝露に起因しています。同種細胞療法は、健康なドナー細胞を、機能不全に陥ったレシピエント細胞や組織の修復、置換、調節に利用することで、広範な慢性疾患に対処する上で大きな可能性を秘めています。例えば、米国国立生物工学情報センター（NCBI）の報告書によると、2050年までに50歳以上で1つ以上の慢性疾患に罹患する人が99.5％増加し、2020年の7,152万人から1億4,266万人に増加すると予測されています。その結果、慢性疾患の増加が同種細胞療法市場の成長を促進しています。

同種細胞療法分野の主要企業は、細胞処理プラットフォームなどの先駆的ソリューションに注力し、市場での地位を固めています。これらのプラットフォームは、単離、精製、拡大、改変、臨床適合性を確保するための品質保証など、治療目的の細胞の調製や操作に使用されるシステムや技術を包含しています。例えば、2024年3月、スウェーデンのヘルスケア企業であるGetinge社は、英国のバイオテクノロジー企業であるCellRev社と共同で、接着細胞拡大（ACE）用の連続細胞処理プラットフォームであるLivit ACEを発表しました。この最先端のプラットフォームは、高度な自動化技術とバイオプロセス技術を統合し、細胞生産の効率と拡張性を著しく向上させる。特筆すべき機能としては、高い純度と生存率を保証するトップクラスの細胞分離・精製システム、十分な治療用細胞を作製するための強固な培養能力、精密な細胞工学のための高度な遺伝子改変ツール、製品の安全性と有効性を保証する厳格な品質管理プロトコールなどが挙げられます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界の市場規模と成長

• 世界の同種細胞療法市場：促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の同種細胞療法市場の実績：規模と成長、2018年～2023年
• 世界の同種細胞療法市場の予測：規模と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界の同種細胞療法市場：タイプ別、実績と予測、2018年～2023年、2023年～2028年、2033年
• 幹細胞療法
• 非幹細胞療法
• 世界の同種細胞療法市場：治療領域別、実績と予測、2018年～2023年、2023年～2028年、2033年
• 血液疾患
• 皮膚疾患
• その他の治療領域
• 世界の同種細胞療法市場：エンドユーザー別、実績と予測、2018年～2023年、2023年～2028年、2033年
• 病院
• 専門クリニック
• 研究機関

第7章 地域別・国別分析

• 世界の同種細胞療法市場：地域別、実績と予測、2018年～2023年、2023年～2028年、2033年
• 世界の同種細胞療法市場：国別、実績と予測、2018年～2023年、2023年～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 同種細胞療法市場：競合情勢
• 同種細胞療法市場：企業プロファイル
  • Novartis AG
  • Bristol Myers Squibb Company
  • Takeda Pharmaceutical Company Limited
  • Bluebird Bio Inc.
  • Poseida Therapeutics Inc.

第31章 その他の大手企業と革新的企業

• Fate Therapeutics Inc.
• Fortress Biotech Inc.
• Sorrento Therapeutics Inc.
• Eureka Therapeutics Inc.
• Juno Therapeutics Inc.
• Adaptimmune Therapeutics plc
• Cellectis SA
• TrakCel Ltd.
• Promab Biotechnologies Inc.
• Ziopharm Oncology Inc.
• Allogene Therapeutics Inc.
• Century Therapeutics Inc.
• Autolus Therapeutics plc
• Bellicum Pharmaceuticals Inc.
• Minerva Biotechnologies Corporation

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと潜在的な分析

第36章 付録

Allogeneic cell therapy involves harvesting cells from a donor to treat a recipient. Its purpose is to replace or repair damaged tissues, modulate immune responses, or address conditions such as cancer, genetic disorders, and autoimmune diseases.

There are two main types of allogeneic cell therapy stem cell therapies and non-stem cell therapies. Stem cell therapies use stem cells to repair or replace damaged tissues or organs, aiming to prevent or treat a range of diseases and conditions. These therapies are applied in various medical fields, including hematological disorders, dermatological disorders, and other therapeutic areas, utilized by hospitals, specialty clinics, and research organizations.

The allogenic cell therapy market research report is one of a series of new reports from The Business Research Company that provides allogenic cell therapy market statistics, including allogenic cell therapy industry global market size, regional shares, competitors with a allogenic cell therapy market share, detailed allogenic cell therapy market segments, market trends, and opportunities, and any further data you may need to thrive in the allogenic cell therapy industry. This allogenic cell therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The allogenic cell therapy market size has grown rapidly in recent years. It will grow from $0.97 billion in 2023 to $1.08 billion in 2024 at a compound annual growth rate (CAGR) of 11.3%. The growth observed in the historical period can be credited to a heightened emphasis on customizing donor cell selection and genetic modifications, an expanding population, a rise in the global burden of chronic diseases, heightened awareness, and an increase in collaborations for biosimilar development.

The allogenic cell therapy market size is expected to see rapid growth in the next few years. It will grow to $1.67 billion in 2028 at a compound annual growth rate (CAGR) of 11.6%. The growth in the forecast is driven by the escalating demand for advanced medical treatments, a burgeoning need for innovative allogeneic cell therapies, a surge in clinical trial activities, growing contributions from patient populations, and escalating income levels. Noteworthy trends anticipated during the forecast period include technological advancements, strategic partnerships, collaborations among major companies, mergers and acquisitions, and the introduction of new products.

The rise in chronic diseases is expected to propel the expansion of the allogeneic cell therapy market. Chronic illnesses, characterized by prolonged duration and necessitating continual medical care, can impede daily functioning and diminish life quality. These conditions' prevalence stems from altered lifestyle habits, genetic inheritance, and exposure to environmental toxins and pollutants. Allogeneic cell therapy offers substantial promise in addressing a broad spectrum of chronic diseases, utilizing healthy donor cells to repair, substitute, or regulate dysfunctional recipient cells or tissues. For example, a report from the National Center for Biotechnology Information (NCBI) projected a 99.5% increase in individuals aged 50 and above suffering from one or more chronic ailments by 2050, rising from 71.52 million in 2020 to 142.66 million. Consequently, the escalating occurrence of chronic diseases propels the allogeneic cell therapy market's growth.

Key players in the allogeneic cell therapy sector are concentrating on pioneering solutions, such as cell processing platforms, to fortify their market standing. These platforms encompass systems and technologies employed in preparing and manipulating cells for therapeutic purposes, including isolation, purification, expansion, modification, and quality assurance to ensure clinical suitability. For instance, in March 2024, Getinge, a Swedish healthcare entity, collaborated with CellRev, a UK biotech firm, to introduce Livit ACE, a continuous cell processing platform for Adherent Cell Expansion (ACE). This cutting-edge platform integrates advanced automation and bioprocessing technologies, markedly augmenting cell production efficiency and scalability. Notable features include top-tier cell isolation and purification systems ensuring high purity and viability, robust expansion capabilities for generating ample therapeutic cells, advanced genetic modification tools for precise cell engineering, and stringent quality control protocols to ensure product safety and efficacy.

In November 2021, Takeda Pharmaceutical Company Limited, a Japanese pharmaceutical giant, acquired GammaDelta Therapeutics Limited for an undisclosed sum. This acquisition aims to bolster Takeda's cell therapy and immuno-oncology capabilities by leveraging GammaDelta Therapeutics' pioneering approach in harnessing gamma-delta (Yδ) T cells. GammaDelta Therapeutics Limited, based in the UK, specializes in developing allogeneic gamma delta T cell therapies.

Major companies operating in the allogeneic cell therapy market are Novartis AG, Bristol Myers Squibb Company, Takeda Pharmaceutical Company Limited, Bluebird Bio Inc., Poseida Therapeutics Inc., Fate Therapeutics Inc., Fortress Biotech Inc., Sorrento Therapeutics Inc., Eureka Therapeutics Inc., Juno Therapeutics Inc., Adaptimmune Therapeutics plc, Cellectis SA, TrakCel Ltd., Promab Biotechnologies Inc., Ziopharm Oncology Inc., Allogene Therapeutics Inc., Century Therapeutics Inc., Autolus Therapeutics plc, Bellicum Pharmaceuticals Inc., Minerva Biotechnologies Corporation, Celyad SA, TILT Biotherapeutics Ltd., CRISPR Therapeutics AG

North America was the largest region in the allogeneic cell therapy market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the allogeneic cell therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the allogeneic cell therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The allogeneic cell therapy market includes revenues earned by entities through induced pluripotent stem cell therapy, hematopoietic stem cell transplantation, mesenchymal stem cell (MSC) therapy, induced pluripotent stem cell (IPSC) therapy and chimeric antigen receptor T cell therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Allogeneic Cell Therapy Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on allogeneic cell therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for allogeneic cell therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The allogeneic cell therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Stem Cell Therapies; Non-Stem Cell Therapies
• 2) By Therapeutic Area: Hematological Disorders; Dermatological Disorders; Other Therapeutic Area
• 3) By End User: Hospitals; Specialty Clinics; Research Organizations
• Companies Mentioned: Novartis AG; Bristol Myers Squibb Company; Takeda Pharmaceutical Company Limited; Bluebird Bio Inc.; Poseida Therapeutics Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Allogeneic Cell Therapy Market Characteristics

3. Allogeneic Cell Therapy Market Trends And Strategies

4. Allogeneic Cell Therapy Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Allogeneic Cell Therapy Market Size and Growth

• 5.1. Global Allogeneic Cell Therapy Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Allogeneic Cell Therapy Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Allogeneic Cell Therapy Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Allogeneic Cell Therapy Market Segmentation

• 6.1. Global Allogeneic Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Stem Cell Therapies
• Non-Stem Cell Therapies
• 6.2. Global Allogeneic Cell Therapy Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hematological Disorders
• Dermatological Disorders
• Other Therapeutic Area
• 6.3. Global Allogeneic Cell Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Specialty Clinics
• Research Organizations

7. Allogeneic Cell Therapy Market Regional And Country Analysis

• 7.1. Global Allogeneic Cell Therapy Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Allogeneic Cell Therapy Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Allogeneic Cell Therapy Market

• 8.1. Asia-Pacific Allogeneic Cell Therapy Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Allogeneic Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Allogeneic Cell Therapy Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Allogeneic Cell Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Allogeneic Cell Therapy Market

• 9.1. China Allogeneic Cell Therapy Market Overview
• 9.2. China Allogeneic Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Allogeneic Cell Therapy Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Allogeneic Cell Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Allogeneic Cell Therapy Market

• 10.1. India Allogeneic Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Allogeneic Cell Therapy Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Allogeneic Cell Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Allogeneic Cell Therapy Market

• 11.1. Japan Allogeneic Cell Therapy Market Overview
• 11.2. Japan Allogeneic Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Allogeneic Cell Therapy Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Allogeneic Cell Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Allogeneic Cell Therapy Market

• 12.1. Australia Allogeneic Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Allogeneic Cell Therapy Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Allogeneic Cell Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Allogeneic Cell Therapy Market

• 13.1. Indonesia Allogeneic Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Allogeneic Cell Therapy Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Allogeneic Cell Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Allogeneic Cell Therapy Market

• 14.1. South Korea Allogeneic Cell Therapy Market Overview
• 14.2. South Korea Allogeneic Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Allogeneic Cell Therapy Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Allogeneic Cell Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Allogeneic Cell Therapy Market

• 15.1. Western Europe Allogeneic Cell Therapy Market Overview
• 15.2. Western Europe Allogeneic Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Allogeneic Cell Therapy Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Allogeneic Cell Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Allogeneic Cell Therapy Market

• 16.1. UK Allogeneic Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Allogeneic Cell Therapy Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Allogeneic Cell Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Allogeneic Cell Therapy Market

• 17.1. Germany Allogeneic Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Allogeneic Cell Therapy Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Allogeneic Cell Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Allogeneic Cell Therapy Market

• 18.1. France Allogeneic Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Allogeneic Cell Therapy Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Allogeneic Cell Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Allogeneic Cell Therapy Market

• 19.1. Italy Allogeneic Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Allogeneic Cell Therapy Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Allogeneic Cell Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Allogeneic Cell Therapy Market

• 20.1. Spain Allogeneic Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Allogeneic Cell Therapy Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Allogeneic Cell Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Allogeneic Cell Therapy Market

• 21.1. Eastern Europe Allogeneic Cell Therapy Market Overview
• 21.2. Eastern Europe Allogeneic Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Allogeneic Cell Therapy Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Allogeneic Cell Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Allogeneic Cell Therapy Market

• 22.1. Russia Allogeneic Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Allogeneic Cell Therapy Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Allogeneic Cell Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Allogeneic Cell Therapy Market

• 23.1. North America Allogeneic Cell Therapy Market Overview
• 23.2. North America Allogeneic Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Allogeneic Cell Therapy Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Allogeneic Cell Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Allogeneic Cell Therapy Market

• 24.1. USA Allogeneic Cell Therapy Market Overview
• 24.2. USA Allogeneic Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Allogeneic Cell Therapy Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Allogeneic Cell Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Allogeneic Cell Therapy Market

• 25.1. Canada Allogeneic Cell Therapy Market Overview
• 25.2. Canada Allogeneic Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Allogeneic Cell Therapy Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Allogeneic Cell Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Allogeneic Cell Therapy Market

• 26.1. South America Allogeneic Cell Therapy Market Overview
• 26.2. South America Allogeneic Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Allogeneic Cell Therapy Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Allogeneic Cell Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Allogeneic Cell Therapy Market

• 27.1. Brazil Allogeneic Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Allogeneic Cell Therapy Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Allogeneic Cell Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Allogeneic Cell Therapy Market

• 28.1. Middle East Allogeneic Cell Therapy Market Overview
• 28.2. Middle East Allogeneic Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Allogeneic Cell Therapy Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Allogeneic Cell Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Allogeneic Cell Therapy Market

• 29.1. Africa Allogeneic Cell Therapy Market Overview
• 29.2. Africa Allogeneic Cell Therapy Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Allogeneic Cell Therapy Market, Segmentation By Therapeutic Area, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Allogeneic Cell Therapy Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Allogeneic Cell Therapy Market Competitive Landscape And Company Profiles

• 30.1. Allogeneic Cell Therapy Market Competitive Landscape
• 30.2. Allogeneic Cell Therapy Market Company Profiles
  • 30.2.1. Novartis AG
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Bristol Myers Squibb Company
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Takeda Pharmaceutical Company Limited
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Bluebird Bio Inc.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Poseida Therapeutics Inc.
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Allogeneic Cell Therapy Market Other Major And Innovative Companies

• 31.1. Fate Therapeutics Inc.
• 31.2. Fortress Biotech Inc.
• 31.3. Sorrento Therapeutics Inc.
• 31.4. Eureka Therapeutics Inc.
• 31.5. Juno Therapeutics Inc.
• 31.6. Adaptimmune Therapeutics plc
• 31.7. Cellectis SA
• 31.8. TrakCel Ltd.
• 31.9. Promab Biotechnologies Inc.
• 31.10. Ziopharm Oncology Inc.
• 31.11. Allogene Therapeutics Inc.
• 31.12. Century Therapeutics Inc.
• 31.13. Autolus Therapeutics plc
• 31.14. Bellicum Pharmaceuticals Inc.
• 31.15. Minerva Biotechnologies Corporation

32. Global Allogeneic Cell Therapy Market Competitive Benchmarking

33. Global Allogeneic Cell Therapy Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Allogeneic Cell Therapy Market

35. Allogeneic Cell Therapy Market Future Outlook and Potential Analysis

• 35.1 Allogeneic Cell Therapy Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Allogeneic Cell Therapy Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Allogeneic Cell Therapy Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer